Melanie Whittington, Head of the Leerink Center for Pharmacoeconomics, interviews Joshua Kresh and Emily Michiko Morris from The IP Policy Institute at the University of Akron School of Law to discuss the critical importance of protecting intellectual property for the biopharmaceutical innovation ecosystem and their recent research around evergreening and patent thickets.

Melanie Whittington, PhD, Head of the Leerink Center for Pharmacoeconomics, interviews Ulrich Neumann, MBA, MSc, MA, Director of Access and Policy Research at Johnson & Johnson, to discuss the motivation behind the recent launch of the J&J Center for U.S. Healthcare Policy Research, the interconnectedness and importance of the various players within the biopharmaceutical R&D ecosystem, and the private capital that is required to develop new drugs.

Resources mentioned in this episode:

https://policyresearch.jnj.com

https://jnjinnovation.com/home

https://www.nature.com/articles/d41573-024-00131-2

https://www.ispor.org/docs/default-source/intl2024/j-j-access-policy-research---ispor-2024---pharma-r-d-ecosystem-investment137860-pdf.pdf?sfvrsn=d28181d4_0

https://www.tandfonline.com/doi/full/10.1080/13696998.2024.2405407

Melanie Whittington, Head of the Leerink Center for Pharmacoeconomics, talks with Gunnar Esiason, Head of Patient Engagement and Patient-Centered Innovation at Raven, RA Capital's healthcare incubator, where they discuss the far-reaching impact of biopharmaceutical innovation, as well as the time, effort, and capital that goes into developing new treatments.

Melanie Whittington, PhD, Head of the Leerink Center for Pharmacoeconomics, interviews Joey Mattingly, PharmD, MBA, PhD, Vice Chair of Research and Associate Professor at the University of Utah, to learn about the history of the pharmaceutical supply chain and the origins of some of its components.

Melanie Whittington, Head of the Leerink Center for Pharmacoeconomics, interviews Jon Campbell, Chief Science Officer of the National Pharmaceutical Council, to discuss what makes biopharmaceutical innovation special and why judging and interpreting their prices is nuanced and requires context.

Melanie Whittington, Head of the Leerink Center for Pharmacoeconomics interviews Elizabeth Franklin, PhD, MSW, Head of U.S. Public Affairs and Patient Advocacy, Oncology with Sanofi where they discuss what it means to be a patient advocate, how innovators and investors can partner with patients, and patients' contributions to drug development and market access.

Melanie Whittington, Head of the Leerink Center for Pharmacoeconomics interviews Kirsten Axelsen, Senior Policy Advisor at DLA Piper & Non-Resident Fellow at the American Enterprise Institute where they discuss drug prices, their opportunity costs, and the effect today’s prices have on future drug developments.

Melanie Whittington, Head of the Leerink Center for Pharmacoeconomics interviews Frank S. David, MD, PhD, Managing Director of Pharmagellan and Professor of the Practice at Tufts University. The healthcare investing and development world and the pharmacoeconomics world have historically operated separately despite drug pricing being core to both worlds. In this episode, Mel and Frank contrast how models are used and built in their respective worlds of pharmacoeconomics and healthcare investing and development.

Melanie Whittington, PhD, Head of the Leerink Center for Pharmacoeconomics interviews Brian Reid, Author of the Cost Curve & the Principal and Founder of Reid Strategic. In this episode they discuss Brian's background in the health journalism space, Generalized Cost Effectiveness Analysis (GCEA), and how the industry can better communicate the impact of healthcare innovation.

In our signature podcast series, Dr. Mel Whittington, a health economist and Head of the Leerink Center for Pharmacoeconomics, talks with people from across the industry to hear their stories and to better understand the societal impact of healthcare innovations. If you’re interested in participating in future podcasts or would like to learn more about the Leerink Center for Pharmacoeconomics, please email [email protected].